Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · IEX Real-Time Price · USD
76.94
+1.00 (1.32%)
At close: May 7, 2024, 4:00 PM
76.00
-0.94 (-1.22%)
After-hours: May 7, 2024, 6:56 PM EDT
Axsome Therapeutics Employees
Axsome Therapeutics had 545 employees on February 13, 2024. The number of employees increased by 172 or 46.11% compared to the previous year.
Employees
545
Change (1Y)
172
Growth (1Y)
46.11%
Revenue / Employee
$460,593
Profits / Employee
-$543,811
Market Cap
3.65B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Feb 13, 2024 | 545 | 172 | 46.11% |
Feb 21, 2023 | 373 | 265 | 245.37% |
Feb 22, 2022 | 108 | 48 | 80.00% |
Feb 22, 2021 | 60 | 15 | 33.33% |
Mar 6, 2020 | 45 | 16 | 55.17% |
Mar 11, 2019 | 29 | 4 | 16.00% |
Mar 2, 2018 | 25 | 3 | 13.64% |
Mar 2, 2017 | 22 | 11 | 100.00% |
Mar 22, 2016 | 11 | 4 | 57.14% |
Oct 13, 2015 | 7 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Surgery Partners | 13,500 |
Integer Holdings | 10,500 |
LivaNova | 2,900 |
Ultragenyx Pharmaceutical | 1,276 |
Alvotech | 1,026 |
Axonics | 797 |
Prestige Consumer Healthcare | 560 |
Crinetics Pharmaceuticals | 290 |
AXSM News
- 1 day ago - Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 6 days ago - Axsome Therapeutics Recognizes May as Mental Health Awareness Month - GlobeNewsWire
- 22 days ago - Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting - GlobeNewsWire
- 27 days ago - Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6 - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder - GlobeNewsWire
- 6 weeks ago - Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients - GlobeNewsWire
- 6 weeks ago - Axsome Therapeutics sleep disorder therapy succeeds in late-stage trial - Reuters
- 6 weeks ago - Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy - GlobeNewsWire